Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Raben

Showing results (31-40 of 161) with videos related to

Pageof 17
Sort By:
Molecular Cancer Therapeutics|September 16, 2008
Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinomaErica L Bradshaw-Pierce, Courtney A Steinhauer, David Raben, et al.
The Laryngoscope|September 20, 2012
Sparing the larynx and esophageal inlet expedites feeding tube removal in patients with stage III-IV oropharyngeal squamous cell carcinoma treated with intensity-modulated radiotherapyNeha Amin, Krishna Reddy, David Westerly, et al.
Expert Review of Anticancer Therapy|March 22, 2003
Interference with EGFR signaling: paradigm for improving radiation response in cancer treatmentDavid Raben, Cataldo Bianco, Barb Helfrich, et al.
Seminars in Oncology|March 15, 2002
ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancerDavid Raben, Barbara A Helfrich, Dan Chan, et al.
International Journal of Radiation Oncology, Biology, Physics|December 27, 2005
ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapyBarbara Frederick, Dan Gustafson, Cataldo Bianco, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Salivary gland cancer: an update on present and emerging therapiesJulie Carlson, Lisa Licitra, Laura Locati, et al.
Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists|April 1, 2015
Dose painting to treat single-lobe prostate cancer with hypofractionated high-dose radiation using targeted external beam radiation: Is it feasible?Arya Amini, David C Westerly, Timothy V Waxweiler, et al.
Radiation Research|September 29, 2015
Bouvardin is a Radiation Modulator with a Novel Mechanism of ActionStefanie A Stickel, Nathan P Gomes, Barbara Frederick, et al.
Radiation Research|September 16, 2020
Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma ModelsBarbara A Frederick, Rohit Gupta, Amandla Atilano-Roque, et al.
Disease Models & Mechanisms|April 21, 2011
Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cellsAnthony Edwards, Mara Gladstone, Petros Yoon, et al.
Pageof 17

Showing results (31-40 of 161) with videos related to

Sort By:
Pageof 17
Molecular Cancer Therapeutics|September 16, 2008
Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinomaErica L Bradshaw-Pierce, Courtney A Steinhauer, David Raben, et al.
The Laryngoscope|September 20, 2012
Sparing the larynx and esophageal inlet expedites feeding tube removal in patients with stage III-IV oropharyngeal squamous cell carcinoma treated with intensity-modulated radiotherapyNeha Amin, Krishna Reddy, David Westerly, et al.
Expert Review of Anticancer Therapy|March 22, 2003
Interference with EGFR signaling: paradigm for improving radiation response in cancer treatmentDavid Raben, Cataldo Bianco, Barb Helfrich, et al.
Seminars in Oncology|March 15, 2002
ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancerDavid Raben, Barbara A Helfrich, Dan Chan, et al.
International Journal of Radiation Oncology, Biology, Physics|December 27, 2005
ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapyBarbara Frederick, Dan Gustafson, Cataldo Bianco, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Salivary gland cancer: an update on present and emerging therapiesJulie Carlson, Lisa Licitra, Laura Locati, et al.
Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists|April 1, 2015
Dose painting to treat single-lobe prostate cancer with hypofractionated high-dose radiation using targeted external beam radiation: Is it feasible?Arya Amini, David C Westerly, Timothy V Waxweiler, et al.
Radiation Research|September 29, 2015
Bouvardin is a Radiation Modulator with a Novel Mechanism of ActionStefanie A Stickel, Nathan P Gomes, Barbara Frederick, et al.
Radiation Research|September 16, 2020
Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma ModelsBarbara A Frederick, Rohit Gupta, Amandla Atilano-Roque, et al.
Disease Models & Mechanisms|April 21, 2011
Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cellsAnthony Edwards, Mara Gladstone, Petros Yoon, et al.
Pageof 17